Most Favored Nation (MFN) pricing represents a major shift in U.S. drug policy. While intended to make medications more affordable, experts during an MFN 2025 webinar warned it could slow innovation, especially in oncology, and disrupt the balance of the healthcare system. Legal challenges, interactions with the IRA and 340B programs and how insurance covers medications will shape its impact on patients, payers and drug companies.

The MFN 2025 webinar hosted by MJH Life Sciences on October 8 brought together experts in health policy, economics and law to discuss how adopting international drug prices could reshape U.S. drug costs, innovation and patient access.

The session was moderated by Ronald W. Lanton III, Esq., a partner at Lanton Law and included speakers Peter Rubin, executive di

See Full Page